PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

REC'D	03	MAR	2005
WIPO		Þ	CT

	plicant's or agent's file reference XG-PB60199	FOR FURTHER	ACTION	See Form PCT/IPEA/416	
PC	emational application No. CT/EP2004/003985	International filing dat 08.04.2004		Priority date (day/monthly 10.04.2003	year)
Inte	ernational Patent Classification (IPC) or na	ational classification and	d IPC		
Ab	1K31/4545, C07D211/32, C07D40	05/06, C07D401/12	² , C07D401/14, A61P2/	5 /28	
	.•				• •
	olicant AXO GROUP LIMITED et al.				
1.	This report is the international preli	annition to the applica	ant according to Afficie 36	s International Preliminan	y Examining
2.	This REPORT consists of a total of	of 6 sheets, including	this cover sheet.		· -
3.	This report is also accompanied by	y ANNEXES, compris	sing:		
ŀ	a. sent to the applicant and to	the International Bur	reau) a total of sheets, a	ıs follows:	
	sheets of the description and/or sheets containing Administrative Instruction	on, claims and/or drawing rectifications authorons).	wings which have been ar orized by this Authority (se	mended and are the basis ee Rule 70.16 and Section	n 607 of the
	☐ sheets which supersede	e earlier shoots, but w	which this Authority consi	iders contain an amendme cated in item 4 of Box No.	ent that goes I and the
	b. (sent to the International Bul sequence listing and/or table Box Relating to Sequence Li	ureau only) a total of ((indicate type and number	or of electronic carrier(s))	
4.	This report contains indications rela	eting to the following			
	_	-	items:	• •	
	— Dudis of the opinic	on			
	— Learner II Holity				
		nt of opinion with rega	ard to novelty, inventive s	step and industrial applica	bility
	Box No. V Reasoned statement	ivention ient under Article 35/3	(2) with record to neverth.		
ĺ	Box No. VI Certain documents	ions and explanations	s supporting such statement	ent .	
		is cited i the international app	· • • = = • •	٠,	• •
	Box No. VIII Certain observatio	the international app.	lication		
		his on the internation	al application	٠.	
Date o	of submission of the demand		Date of completion of this	report .	
	1.2004		01.03.2005		
Name prelim	and mailing address of the international ninary examining authority:	Authorized Officer			
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Cortés, J Telephone No. +49 89 239	99-8206	A PARTIE OF THE	
			1		- AND SALE

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

☆ International application No.
☆ PCT/EP2004/003985

_	Box No	. I Basis of the report			
1	. With regard to the language , this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.				
		s report is based on translations from the original language into the forch is the language of a translation furnished for the purposes of: international search (under Rules 12.3 and 23.1(b)) publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3)	ollowing language ,		
2.	. With reg	pard to the elements* of the international application, this report is be en furnished to the receiving Office in response to an invitation under some some some and are not annexed to this report):	ased on (replacement sheets which r Article 14 are referred to in this		
	Descrint	ion, Pages			
	1-34	as originally filed	74.		
	Claims, I	Numbers			
	1-19	as originally filed			
	□ a se	quence listing and/or any related table(s) - see Supplemental Box Re	elating to Sequence Listing		
3.	☐ The ☐ tl ☐ tl ☐ tl ☐ tl ☐ tl	amendments have resulted in the cancellation of: ne description, pages ne claims, Nos. ne drawings, sheets/figs ne sequence listing (specify): ny table(s) related to sequence listing (specify):			
4.	Supplemed the supplement of th	report has been established as if (some of) the amendments annexe een made, since they have been considered to go beyond the disclorantal Box (Rule 70.2(c)). The description, pages e claims, Nos. The drawings, sheets/figs The esequence listing (specify): The provided High sequence listing (specify):	ed to this report and listed below sure as filed, as indicated in the		
		tem 4 applies, some or all of these sheets may be n	marked "superseded "		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003985

		x No. III Non-establishment plicability	of o	oinion with regard to novelty, inventive step and industrial		
1.	The	he questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- bvious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
	Ø	claims Nos. 17				
		because:				
	×	the said international application, or the said claims Nos. 17 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the written form		has not been furnished		
				does not comply with the standard		
		the computer readable form		has not been furnished		
				does not comply with the standard		
E		the tables related to the nucleot not comply with the technical re	ide a quire	nd/or amino acid sequence listing, if in computer readable form only, do ments provided for in Annex C-bis of the Administrative Instructions.		
ב	J	See separate sheet for further d	etails	· S		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/003985

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

3,4,8-19

No: Claims

1,2,5-7

Inventive step (IS)

Yes: Claims

1-19

No: Claims

Industrial applicability (IA)

Yes: Claims

1-16, 18-19

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

: International application No.

PCT/EP2004/003985

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 17 relateS to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion with regard to the industrial applicability will be formulated for this claim (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The following documents were cited in the International Search Report:

D1: WO 02/12214 A (ORTHO MCNEIL PHARM INC (US)) 14 February 2002 (2002-02-14)

D2: WO 02/068388 A (MERCK & CO INC (US)) 6 September 2002 (2002-09-06)

D3: WO 02/076440 A (UPJOHN CO (US)) 3 October 2002 (2002-10-03)

D4: DE 44 07 139 A (THOMAE GMBH DR K (D)) 7 September 1995 (1995-09-07)

Novelty (Article 33(2) PCT)

The compounds of the present claims 1, 2 and 5-7 overlap with the generic group disclosed in claim 1 of D4. The overlap is not a novel selection, since the structural features of said claims are disclosed in D1. The mentioned claims are therefore not novel.

The present compounds differ from the compounds in D1 and D3 in the group R1-Z and from the compounds in D2 in the group -O-R4.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/003985

Inventive Step (Article 33(3) PCT)

D1 discloses histamine H3 antagonists and can be regarded as the closests prior art. D2 and D3 disclose compounds for the treatment of Alzheimer's.

The problem of the invention was the provision of further histamine H3 antagonists for the treatment of neurological diseases such as Alzheimer's.

D2 and D3 do not disclose the alleged pharmacology, but even if a skilled person had combined e.g. D1 with D2 he would not have been prompted to provide the present compounds, since D1 does not disclose any structurally related examples (the present compounds differ from all examples in D1 not only in R1-Z but in further structural features, such as e.g. the direct link between the piperidine and the phenyl and/or the orientation of the piperidine etc.).

D3 discloses structurally related examples from which the present compounds differ only in the group R1-Z. However a skilled person faced with the above mentioned probelm would not have combined D2 with D3, since none of these compounds discloses the alleged pharmacology.

The present invention is therefore based on an inventive step.